Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
3 very important steps to consider.
1) land ( check)
2) funding
3) permits
2 seems to be in place and pending. My opinion, depends on results of permits. Permits happen, all he'll breaks loose. Anyone know how long it takes for a federal permit to go through?
I understand your concerns. I don't believe onvo is stupid enough to let this happen to them in a long term fashion. They will ajust prices accordingly. Having patents and or IP prevents these companies, if onvo somehow went under, from using their technology. It is ultimately 10 times better than what they had before. Fortunately they are stuck with us for good or I'll.
Over reaction to delay in revenue, not loss in revenue. Very inert conference call.
3D Bioprinting Market Worth 1,332.6 Million USD by 2021
PR NewswireFebruary 1, 2017
PUNE, India, February 1, 2017 /PRNewswire/ --
According to a new market research report "3D Bioprinting Market by Technology (Microextrusion, Inkjet, Laser, Magnetic), Material (Cells, Hydrogels, Extracellular Matrices, Biomaterials), Application (Clinical (Bone, Cartilage, Skin) & Research (Regenerative Medicine)) - Global Forecasts to 2021", published by MarketsandMarkets, This report studies the global 3D Bioprinting Market over the forecast period of 2016 to 2021. This market is expected to reach USD 1,332.6 Million by 2021, at CAGR of 26.5% from 2016 to 2021.
(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )
Browse 74 market data Tables and 39 Figures spread through 143 Pages and in-depth TOC on "3D Bioprinting Market"
http://www.marketsandmarkets.com/Market-Reports/3d-bioprinting-market-170201787.html
Early buyers will receive 10% customization on this report.
Key factors such as rising demand for organ transplantation, growing R&D in 3D bioprinting, increasing public and private investments in research, and rising use of 3D bioprinting in drug discovery are driving the growth of this market. However, the limitations of biomaterial-based products, lack of complete automation in 3D bioprinting, and socio-ethical concerns related to the use of 3D bioprinted products are the major challenges in this market.
By technology, the global 3D Bioprinting Market is segmented into four broad categories, namely, microextrusion, inkjet, laser, and magnetic 3D bioprinting. The microextrusion 3D bioprinting technology is estimated to command the largest share of the market in 2016, due to its affordability, among other factors.
On the basis of application, the market is segmented into clinical applications (including skin, bone & cartilage, and blood vessels) and research applications (including drug research, regenerative medicine, and 3D cell culture).
Speak To Analyst: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=170201787
On the basis of procedure, the market is segmented into thoracotomy and minimally invasive surgeries. The The research applications segment holds the largest share in the 3D bioprinting market; it is projected to witness high growth during the forecast period. Increasing initiatives by market players and university scientists in the 3D bioprinting field form the major factor driving the growth of this segment.
Based on material, the 3D Bioprinting Market is further segmented into extracellular matrices, hydrogels, living cells, and biomaterials. The living cells segment is expected to account for the largest share of the market in 2016. Increasing R&D initiatives for the use of living cells in 3D bioprinting form one of the major factors driving the growth of the market.
As of 2016, North America holds the largest share of the global 3D bioprinting market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR from 2016 to 2021. A number of factors such as increase in overall and stem cell research activity, growing demand for organ transplantation, and rising initiatives by market players are propelling the growth of the Asia-Pacific 3D bioprinting market.
Download PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=170201787
As of 2015, the 3D Bioprinting Market is dominated by Organovo Holdings Inc. (U.S.), EnvisionTEC GmbH (Germany), and Nano3D Biosciences, Inc. (U.S.). Other players in this market include Cyfuse Biomedical K.K. (Japan), BioBots (U.S.), Aspect Biosystems Ltd. (Canada), 3Dynamic Systems Ltd. (U.K.), regenHU Ltd (Switzerland), Cellink (Sweden), Regenovo Biotechnology Co., Ltd. (China), Poietis (France), and GeSiM (Germany).
Browse Related Reports:
3D Printing Medical Devices Market by Component (3D Printers, 3D Bioprinters, Materials, Services & Software), Technology (EBM, LBM, Photopolymerization, 3DP, and DD) & by Medical Products (Surgical Guides, Equipment, Implant) - Global Forecast to 2020.
http://www.marketsandmarkets.com/Market-Reports/3d-printing-medical-devices-market-90799911.html
3D Cell Culture Market by Technology (Scaffold Based, Scaffold Free), Application (Cancer Cell Research, Cell-based Assays/Toxicity Screening), End- Users (Biotechnology & Pharmaceuticals Industries) and Geography- Global Forecast to 2021.
http://www.marketsandmarkets.com/Market-Reports/3d-cell-culture-market- 191072847.html
Something is afoot? At first, I was highly upset about the ipo that just happened, still not happy. But , the more I thought about it, I think something big may happen. If I'm not mistaken, before the ipo they had 18 months of operating cash on hand. We were told there should be no need for dilution. Boom, it happened. why? Cash was suddenly needed, why? I do believe something is going to be announced on thurs. We shall see, either way I do expect a explanation for good or ill on the influx of cash needed.
Thanks for the bold face lies last conference call onvo. Better be a strong reason for this with a explanation. Say goodbye to the stock price! What's up keith?
Soilent green, for those of you old enough to remember, is coming to fruition.
As a result of a good call, I do believe we continue the long March up. Kidney release at euro tox. 2016. It is held on October 24th-26th. Good things happening
Loss of -09 a share with 891,000 revenue. It beats. Good number's
For me, all depends on the #'s tomorrow. Will definitely leave core in no matter what though.
Congratulations ONVO, you just closed at the high of the day and a 52 week high for a closing number. All arrows are pointing up. Beat numbers tomorrow and we go to five very shortly. Good luck all and may the onvo be with you!
CFO, who knows. They seem to be taking their time on this to make sure that they have the right fit. I do think we will get a small bump on the up listening, especially if we have solid earnings. I'm wondering when they will announce full launch of the kidney assay's. Thursday or slightly before the conference on the 29th?
CFO, who knows. They seem to be taking their time on this to make sure that they have the right fit. I do think we will get a small bump on the up listening, especially if we have solid earnings. I'm wondering when they will announce full launch of the kidney assay's. Thursday or slightly before the conference on the 29th?
If we can break and hold, it sets up nicely for next week's earnings report. In line or beats expectations and this stock is off to the races.
I totally agree, skin is most likely next on the list. The partnership is well over a year old now. I would expect results from them very soon. I would like to know how close they are to cracking the liver patch puzzle?
The possibilities are endless. I have a friend who had cancer in between his jaw and eye socket. They had to remove his upper jaw to get to it. They grafted a bone in to replace it. It didn't take. He wondered if they could help him. I said to him, in the very near future, probably yes. Just about Anything is possible with this technology.
Did not get a chance to see the webinar. Any feed back from viewers? Great day once again, more strong volume.
Over 2 million in volume today, outstanding! Volume stron, charts looking very favorable. Long March north should continue.
June B numbers are in for shorts. And they are back. Numbers from shortsqueeze.com say they are up 9% from June A numbers. Not Good.
Organovo Holdings Incorporated
$ 3.10
ONVO
-0.25
Short Squeeze Ranking™
view
Daily Short Sale Volume
view
Daily Naked Short Selling List
view
Short Interest (Shares Short)
11,182,300
Short Interest Ratio (Days To Cover)
14.6
Short Percent of Float
13.12 %
Short % Increase / Decrease
9 %
Short Interest (Shares Short) - Prior
10,213,800
Shares Float
85,210,000
Trading Volume - Today
952,324
Trading Volume - Average
765,800
Trading Volume - Today vs. Average
124.36%
% Owned by Insiders
8.36%
% Owned by Institutions
27.90%
Earnings Per Share
PE Ratio
Market Cap.
$ 286,409,000
% From 52-Wk High ($ 4.13)
-24.94%
% From 52-Wk Low ($ 1.60)
93.75%
% From 200-Day MA ($ 2.47)
25.48%
% From 50-Day MA ($ 2.87)
8.07%
Sector
Industry
Exchange
AMX
Record Date
2016-JuneB
Considering what happened today, we got off pretty light. We just fell back into channel on the chart. Overall, this stock still looks primeded to run more from the looks of the charts.
When I say blood bath, I mean market. Don't want to get flagged by the government as a subversive!
Good luck to all tomorrow. May the earnings and the news be bountiful. See you all on the other side.
May B short numbers out, slightly down.
Organovo Holdings Incorporated
$ 2.78
ONVO
0.03
Short Squeeze Ranking™
view
Daily Short Sale Volume
view
Daily Naked Short Selling List
view
Short Interest (Shares Short)
10,690,500
Short Interest Ratio (Days To Cover)
28.3
Short Percent of Float
12.57 %
Short % Increase / Decrease
-1 %
Short Interest (Shares Short) - Prior
10,818,700
Shares Float
85,070,000
Trading Volume - Today
351,262
Trading Volume - Average
377,100
Trading Volume - Today vs. Average
93.15%
% Owned by Insiders
8.36%
% Owned by Institutions
27.90%
Earnings Per Share
PE Ratio
Market Cap.
$ 256,899,800
% From 52-Wk High ($ 5.82)
-52.23%
% From 52-Wk Low ($ 1.60)
73.75%
% From 200-Day MA ($ 2.48)
12.01%
% From 50-Day MA ($ 2.61)
6.49%
Sector
Industry
Exchange
AMX
Record Date
2016-MayB
Opinions, do we get a run up in price? Or do we get a beat down buy shorts. Do we get full disclosure , as promised or do we get the same old song and dance.
Nice drubbing today, ouch!
Short numbers in for May A. Shortsqeeze.com
ONVO
-0.11
Short Squeeze Ranking™
view
Daily Short Sale Volume
view
Daily Naked Short Selling List
view
Short Interest (Shares Short)
10,818,700
Short Interest Ratio (Days To Cover)
22.4
Short Percent of Float
12.72 %
Short % Increase / Decrease
-7 %
Short Interest (Shares Short) - Prior
11,673,800
Shares Float
85,070,000
Trading Volume - Today
306,595
Trading Volume - Average
483,200
Trading Volume - Today vs. Average
63.45%
% Owned by Insiders
8.36%
% Owned by Institutions
27.90%
Earnings Per Share
PE Ratio
Market Cap.
$ 243,962,400
% From 52-Wk High ($ 5.82)
-54.64%
% From 52-Wk Low ($ 1.60)
65.00%
% From 200-Day MA ($ 2.52)
4.60%
% From 50-Day MA ($ 2.50)
5.59%
Sector
Industry
Exchange
AMX
Record Date
2016-MayA
We are entering a very critical phase. We will get a snapshot on the 12th, but ultimately the year end in June will tell us what we have. It will be put up or shut up time.
I think people are missing the point here. Onvo does have a revolutionary product, but it's just getting off the ground. The company has told you everything you need to know for probably the next 5 months. Nothing will be revealed until the june year end report. Until then, the stock price will more than likely languish, with a minor push coming for the next quarterly. Don't be surprised to see a 52 wk. low at some point soon. Not hating, just being realistic. This will be huge, just not yet.
It would be very interesting too see how much of the 48% short has already covered. I am assuming, which is always dangerous, it would take a while. We shall see the numbers on the 11th. I can't imagine why any short would be holding at this point.
Hoping for full steam ahead but this thing is running hot, I wouldn't be surprised if it pulls back today and consolidates. I do believe we will be testing 40 soon though. Only time will tell. GLTA
Another quality day, very nice!
Outstanding close today. New investment with big $. Higher highs = $. Shorts should be running for the hills.
If we can break 29.65 and hold, nothing but blue sky all the way to 38.
Good spiked with bad, missed on earnings but had validation on kidney ahead of schedule.
New Jefferies rating
http://www.streetinsider.com/dr/news.php?id=10963996
Momentum has caught up to them, steamroller!!!
Shorty tried hard today. The average cover date is 15.3 for them. This falls on roughly Tuesday or Wednesday. Should be a very nice week
Hope we get some new contracts out of this junket.
http://www.organovo.com/tissues-services/upcoming-events
Nice to see the price trying to hold ground despite high short action still happening. sept A short #'s.
http://shortsqueeze.com/?symbol=onvo&submit=Short+Quote%99